Skip to main content
SpringerLink
Log in

Grundlagen der medikamentösen Therapie

  • Chapter
  • First Online:
Seltene Lungenerkrankungen

  • 3279 Accesses

Zusammenfassung

In diesem Kapitel werden verschiedene medikamentöse Verfahren zur Behandlung seltener Lungenerkrankungen, mit Fokus auf die interstitiellen Lungenerkrankungen, dargestellt. Die vorgeschlagenen Verabreichungswege und Dosierungen sowie die Nebenwirkungen und notwendige Kontrolluntersuchungen werden diskutiert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Abd Rahman NA, Tett SE et al (2013) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clin Pharmacokinet 52(5):303–331

    Article  CAS  PubMed  Google Scholar 

  • Alcorn N, Saunders S et al (2009) Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 32(12):1123–1134

    Article  CAS  PubMed  Google Scholar 

  • Allen J (2006) Acute eosinophilic pneumonia. Semin Respir Crit Care Med 27(2):142–147

    Article  PubMed  Google Scholar 

  • Antonioli E, Nozzoli C et al (2005) Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Ann Oncol 16(11):1849–1850

    Article  CAS  PubMed  Google Scholar 

  • Araiza-Casillas R, Cardenas F et al (2004) Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 13(2):119–124

    Article  CAS  PubMed  Google Scholar 

  • Barnes PJ (2010) Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 120(2–3):76–85

    Article  CAS  PubMed  Google Scholar 

  • Baughman RP, Judson MA et al (2002) Thalidomide for chronic sarcoidosis. Chest 122(1):227–232

    Article  CAS  PubMed  Google Scholar 

  • Baughman RP, Lower EE (2014) Medical therapy of sarcoidosis. Semin Respir Crit Care Med 35(3):391–406

    Article  PubMed  Google Scholar 

  • Baughman RP, Nunes H et al (2013) Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 41(6):1424–1438

    Article  PubMed  Google Scholar 

  • von der Beck D, Loh B et al (2014) Antifibrotic treatment. Dtsch Med Wochenschr 139(49):2523–2525

    Article  PubMed  Google Scholar 

  • Bharadwaj A, Haroon N (2004) Peripheral neuropathy in patients on leflunomide. Rheumatology (Oxford) 43(7):934

    Article  CAS  Google Scholar 

  • Brummaier T, Pohanka E et al (2013) Using cyclophosphamide in inflammatory rheumatic diseases. Eur J Intern Med 24(7):590–596

    Article  CAS  PubMed  Google Scholar 

  • Carson KR, Evens AM et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20):4834–4840

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Cohen SB, Iqbal I (2003) Leflunomide. Int J Clin Pract 57(2):115–120

    CAS  PubMed  Google Scholar 

  • Conway R, Low C et al (2014) Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 66(4):803–812

    Article  CAS  PubMed  Google Scholar 

  • Dalrymple JM, Stamp LK et al (2008) Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 58(11):3299–3308

    Article  CAS  PubMed  Google Scholar 

  • van Ede AE, Laan RF et al (2002) Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41(6):658–665

    Article  Google Scholar 

  • Egan JJ, Remund KF et al (2008) Sirolimus for lymphangioleiomyomatosis lesions. N Engl J Med 358(18):1963–1964 (author reply 1964)

    Article  CAS  PubMed  Google Scholar 

  • Fauci AS, Dale DC et al (1976) Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 84(3):304–315

    Article  CAS  PubMed  Google Scholar 

  • Faurschou M, Sorensen IJ et al (2008) Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35(1):100–105

    CAS  PubMed  Google Scholar 

  • Gearry RB, Barclay ML (2005) Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 20(8):1149–1157

    Article  CAS  PubMed  Google Scholar 

  • van der Goes MC, Jacobs JW et al (2014) The value of glucocorticoid co-therapy in different rheumatic diseases – positive and adverse effects. Arthritis Res Ther 16:2 (Suppl 2)

    Article  Google Scholar 

  • Grimminger F, Gunther A, Vancheri C (2015) The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J 45(5):1426–1433

    Article  CAS  PubMed  Google Scholar 

  • Grobost V, Khouatra C et al (2014) Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis. Orphanet J Rare Dis 9(1):191

    Article  PubMed Central  PubMed  Google Scholar 

  • Guillevin L (2013) Infections in vasculitis. Best Pract Res Clin Rheumatol 27(1):19–31

    Article  PubMed  Google Scholar 

  • Guillevin L, Cordier JF et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40(12):2187–2198

    Article  CAS  PubMed  Google Scholar 

  • Guillevin L, Pagnoux C et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371(19):1771–1780

    Article  PubMed  Google Scholar 

  • Haroche J, Cohen-Aubart F et al (2013) Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121(9):1495–1500

    Article  CAS  PubMed  Google Scholar 

  • Haroche J, Cohen-Aubart F et al (2015) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF (V600E)-mutated Erdheim-Chester disease. J Clin Oncol 33(5):411–418

    Article  CAS  PubMed  Google Scholar 

  • Horton MR, Santopietro V et al (2012) Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 157(6):398–406

    Article  PubMed  Google Scholar 

  • Imokawa S, Colby TV et al (2000) Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 15(2):373–381

    Article  CAS  PubMed  Google Scholar 

  • Jick SS, Lieberman ES et al (2006) Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55(1):19–26

    Article  PubMed  Google Scholar 

  • Judson MA (2012) The treatment of pulmonary sarcoidosis. Respir Med 106(10):1351–1361

    Article  PubMed  Google Scholar 

  • Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31(6):456–473

    Article  CAS  PubMed  Google Scholar 

  • King TE Jr, Bradford WZ et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083–2092

    Article  PubMed  Google Scholar 

  • Lennard L, Van Loon JA et al (1989) Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 46(2):149–154

    Article  CAS  PubMed  Google Scholar 

  • Luqmani RA (2014) State of the art in the treatment of systemic vasculitides. Front Immunol 5:471

    Article  PubMed Central  PubMed  Google Scholar 

  • McCormack FX, Inoue Y et al (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364(17):1595–1606

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Mehta P (2003) Thalidomide and thrombosis. Clin Adv Hematol Oncol 1(8):464–465

    PubMed  Google Scholar 

  • Moes DJ, Guchelaar HJ, de Fijter JW (2015) Sirolimus and everolimus in kidney transplantation. Drug Discov Today 20(10):1243–1249

    Article  CAS  PubMed  Google Scholar 

  • Morawska M, Grzasko N et al (2014) Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol (Epub ahead of print) doi:10.1002/hon.2149.

    Google Scholar 

  • Mukhtyar C, Guillevin L et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310–317

    Article  CAS  PubMed  Google Scholar 

  • Noble PW, Albera C et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760–1769

    Article  CAS  PubMed  Google Scholar 

  • Ostensen M, Lockshin M et al (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 47:iii28–iii31 (Suppl 3)

    Article  Google Scholar 

  • Pagnoux C, Mahendira D et al (2013) Fertility and pregnancy in vasculitis. Best Pract Res Clin Rheumatol 27(1):79–94

    Article  PubMed  Google Scholar 

  • Pagnoux C, Mahr A et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359(26):2790–2803

    Article  CAS  PubMed  Google Scholar 

  • Papiris SA, Tsirigotis P et al (2014) Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose. Clin Drug Investig 34(8):553–564

    Article  CAS  PubMed  Google Scholar 

  • Penn I (1990) Cancers complicating organ transplantation. N Engl J Med 323(25):1767–1769

    Article  CAS  PubMed  Google Scholar 

  • Raj R, Nugent K (2013) Leflunomide-induced interstitial lung disease (a systematic review). Sarcoidosis Vasc Diffuse Lung Dis 30(3):167–176

    CAS  PubMed  Google Scholar 

  • Ramiro S, Gaujoux-Viala C et al (2014) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):529–535

    Article  CAS  PubMed  Google Scholar 

  • Richeldi L, du Bois RM et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082

    Article  PubMed  Google Scholar 

  • Roubille C, Haraoui B (2014) Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 43(5):613–626

    Article  CAS  PubMed  Google Scholar 

  • Ruiz-Irastorza G, Ramos-Casals M et al (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20–28

    Article  CAS  PubMed  Google Scholar 

  • Sahoo DH, Bandyopadhyay D et al (2011) Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 38(5):1145–1150

    Article  CAS  PubMed  Google Scholar 

  • Saven A, Figueroa ML et al (1993) 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med 329(10):734–735

    Article  CAS  PubMed  Google Scholar 

  • Schaberg T, Bauer T et al (2012) Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP). Pneumologie 66(3):133–171

    Article  CAS  PubMed  Google Scholar 

  • Scheffert JL, Raza K (2014) Immunosuppression in lung transplantation. J. Thorac Dis 6(8):1039–1053

    Google Scholar 

  • Schiff MH, Jaffe JS et al (2014) Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73(8):1549–1551

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Singh JA, Wells GA et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2:CD008794

    PubMed  Google Scholar 

  • Stockley RA, Miravitlles M et al (2013) Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis 8:149

    Article  PubMed Central  PubMed  Google Scholar 

  • Strand V, Cohen S et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159(21):2542–2550

    Article  CAS  PubMed  Google Scholar 

  • Suissa S, Hudson M et al (2006) Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 54(5):1435–1439

    Article  CAS  PubMed  Google Scholar 

  • Swigris JJ, Olson AL et al (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130(1):30–36

    Article  CAS  PubMed  Google Scholar 

  • Talar-Williams C, Hijazi YM et al (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124(5):477–484

    Article  CAS  PubMed  Google Scholar 

  • Tazawa R, Inoue Y et al (2014) Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. Chest 145(4):729–737

    Article  CAS  PubMed  Google Scholar 

  • Tazawa R, Trapnell BC et al (2010) Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 181(12):1345–1354

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Teschler H (2015) Long-term experience in the treatment of alpha1-antitrypsin deficiency: 25 years of augmentation therapy. Eur Respir Rev 24(135):46–51

    Article  PubMed  Google Scholar 

  • Vargesson N (2015) Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today 105(2):140–156

    Article  CAS  PubMed  Google Scholar 

  • van Vollenhoven RF, Emery P et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72(9):1496–1502

    Article  PubMed Central  PubMed  Google Scholar 

  • Vorselaars AD, Wuyts WA et al (2013) Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 144(3):805–812

    Article  CAS  PubMed  Google Scholar 

  • Wang K, Zhang H et al (2004) Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 36(7):2068–2070

    Article  CAS  PubMed  Google Scholar 

  • Wong L, Harper L et al (2015) Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis. Nephrol Dial Transplant 30:i164–i170 (suppl 1)

    Article  PubMed  Google Scholar 

  • Xu X, Blinder L et al (1997) In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 159(1):167–174

    CAS  PubMed  Google Scholar 

  • Yale SH, Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71(1):5–13

    Article  CAS  PubMed  Google Scholar 

Hilfreiche Websites

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum Gießen Marburg GmbH, Standort Gießen, Klinikstraße 36, 35392, Gießen, Deutschland

    Dr. med. Fotios Drakopanagiotakis

  2. Medizinische Klinik und Poliklinik II, Universitätsklinikum Gießen Marburg GmbH, Klinikstraße 36, 35392, Gießen, Deutschland

    Prof. Dr. med. Andreas Günther

Authors
  1. Dr. med. Fotios Drakopanagiotakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Andreas Günther
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fotios Drakopanagiotakis .

Editor information

Editors and Affiliations

  1. Pneumologie und Beatmungsmediz, Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Michael Kreuter

  2. Ruhrlandklinik, Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany

    Ulrich Costabel

  3. Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Felix Herth

  4. Zentrum für Pneumologie & Thoraxchir., LungenClinic Großhansdorf, Großhansdorf, Schleswig-Holstein, Germany

    Detlef Kirsten

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Drakopanagiotakis, F., Günther, A. (2016). Grundlagen der medikamentösen Therapie. In: Kreuter, M., Costabel, U., Herth, F., Kirsten, D. (eds) Seltene Lungenerkrankungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48419-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48419-7_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48418-0

  • Online ISBN: 978-3-662-48419-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation